Fig. 5: Phenotypic comparison of BMS-98654 and orva-cel. | Leukemia

Fig. 5: Phenotypic comparison of BMS-98654 and orva-cel.

From: Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

Fig. 5

BMS-986354 exhibits a higher proportion of central memory and a lower proportion of effector memory and TEMRA in both CD4 and CD8 compartments (A). Following stimulation, BMS-98654 exhibits enhanced INFγ, IL-2 and TNFα when compared to orva-cel (B). Immune markers: naive-like, CCR7 + CD45RA + ; Central Memory CCR7 + CD45RA-; Effector Memory, CCR7-CD45RA- T effector memory RA (TEMRA), CD45RA + CCR7-. ****P ≤ 0.0001. IFNγ interferon gamma, IL-2 interleukin-2, TNFα tumor necrosis factor alpha.

Back to article page